206 related articles for article (PubMed ID: 32599072)
1. Role of mTOR As an Essential Kinase in SCLC.
Kern JA; Kim J; Foster DG; Mishra R; Gardner EE; Poirier JT; Rivard C; Yu H; Finigan JH; Dowlati A; Rudin CM; Tan AC
J Thorac Oncol; 2020 Sep; 15(9):1522-1534. PubMed ID: 32599072
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R; Deng X; Sun SY; Rossi MR; Sica GL; Ramalingam SS; Khuri FR
J Transl Med; 2016 May; 14(1):111. PubMed ID: 27142472
[TBL] [Abstract][Full Text] [Related]
3. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer.
Majeed S; Aparnathi MK; Nixon KCJ; Venkatasubramanian V; Rahman F; Song L; Weiss J; Barayan R; Sugumar V; Barghout SH; Pearson JD; Bremner R; Schimmer AD; Tsao MS; Liu G; Lok BH
Clin Cancer Res; 2022 May; 28(9):1966-1978. PubMed ID: 35165102
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract][Full Text] [Related]
6. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
[No Abstract] [Full Text] [Related]
7. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
8. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
[TBL] [Abstract][Full Text] [Related]
10. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
11. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
12. Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
Kawabata S; Connis N; Gills JJ; Hann CL; Dennis PA
Anticancer Res; 2021 Jan; 41(1):91-99. PubMed ID: 33419802
[TBL] [Abstract][Full Text] [Related]
13. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
Polley E; Kunkel M; Evans D; Silvers T; Delosh R; Laudeman J; Ogle C; Reinhart R; Selby M; Connelly J; Harris E; Fer N; Sonkin D; Kaur G; Monks A; Malik S; Morris J; Teicher BA
J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27247353
[TBL] [Abstract][Full Text] [Related]
14. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
Karachaliou N; Papadaki C; Lagoudaki E; Trypaki M; Sfakianaki M; Koutsopoulos A; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
PLoS One; 2013; 8(9):e74611. PubMed ID: 24058603
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
17. Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer.
Wang Z; Fu S; Zhao J; Zhao W; Shen Z; Wang D; Duan J; Bai H; Wan R; Yu J; Wang S; Chen H; Chen B; Wang L; Wang J
Cancer Lett; 2019 Jan; 440-441():180-188. PubMed ID: 30347283
[TBL] [Abstract][Full Text] [Related]
18. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer.
Kumari A; Gesumaria L; Liu YJ; Hughitt VK; Zhang X; Ceribelli M; Wilson KM; Klumpp-Thomas C; Chen L; McKnight C; Itkin Z; Thomas CJ; Mock BA; Schrump DS; Chen H
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36883564
[TBL] [Abstract][Full Text] [Related]
20. Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
Yang X; Bai F; Xu Y; Chen Y; Chen L
Cell Physiol Biochem; 2017; 43(3):1126-1139. PubMed ID: 28977798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
